UK scientists from the Institute of Cancer Research have developed a saliva test that may improve the early detection of prostate cancer by analyzing specific DNA mutations associated with increased risk. This test is designed to identify men who are at a higher genetic risk of developing aggressive prostate cancers, potentially allowing for timely intervention through biopsies and MRI scans.
In a recent study, researchers focused on men aged 55 to 69, inviting those in the top 10% of risk scores for further testing. Out of 745 men assessed, 187 were diagnosed with prostate cancer, with 74 aggressive tumors identified that current testing methods might have missed. The study has been published in the New England Journal of Medicine and suggests that the saliva test could be a significant step forward in prostate cancer management.
However, experts caution that while the test shows promise, it has not yet been proven to save lives. Concerns remain about the potential risks of false positives and the effectiveness of screening compared to current methods, which primarily measure prostate-specific antigen (PSA) levels in the blood. The saliva test still requires extensive evaluation and adaptation for diverse populations, as initial research mainly involved individuals of European descent.
The research team plans to integrate this saliva test into the forthcoming Transform trial, aimed at refining prostate cancer screening in the UK. While some experts, like Prof. Michael Inouye, see the study as a landmark in genetic risk assessment, they acknowledge that widespread implementation within the NHS may take several years. The ongoing discourse surrounding prostate cancer screening continues to evolve, especially following high-profile cases like that of Olympic cyclist Sir Chris Hoy.